Therapeutic effects of fludarabine-cyclophosphamide combined therapy in Iranian patients with B-cell chronic lymphocytic leukemia
| Author | Kamran Moshfeghi | en |
| Author | Dr Ghasem Mosayebi | en |
| Orcid | Dr Ghasem Mosayebi [0000-0003-3877-0783] | en |
| Issued Date | 2015-03-30 | en |
| Abstract | Introduction: The aim of this study was to investigate the efficacy of fludarabine-cyclophosphamide combination in treatment of Iranian patients with B-cell chronic lymphocytic leukemia (B-CLL). Materials and Methods: Between April 2011 and July 2013, 20 patients with B-CLL (median age 63 years) received a regimen that consisted of fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2, days 1-3, orally, every 4 weeks, for a maximum of 6 courses. Clinical appearances and percentage of CD5+/CD19+ cells as minimal residual disease detected by flow cytometry before and 6 months after treatment. Results: The frequency of CD5+, CD5+/CD19+ and CD19+-cells were significantly high (70-90 %) in the peripheral blood of all the patients, before treatment. The percentage of CD2 and CD3+-cells were significantly increased after treatment (p | en |
| DOI | https://doi.org/ | en |
| Keyword | Leukemia | en |
| Keyword | Lymphocytic | en |
| Keyword | Chronic | en |
| Keyword | B-Cell | en |
| Keyword | Cyclophosphamide | en |
| Keyword | Flow cytometry | en |
| Keyword | سلول تی | en |
| Keyword | سرطان خون | en |
| Keyword | لنفوسیتی مزمن | en |
| Keyword | سنجش جریان سلولی | en |
| Keyword | سیکلوفسفامید | en |
| Publisher | Brieflands | en |
| Title | Therapeutic effects of fludarabine-cyclophosphamide combined therapy in Iranian patients with B-cell chronic lymphocytic leukemia | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- article-1-2394-fa.pdf.pdf
- Size:
- 270.66 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF